Designing better cancer immunotherapies using advanced computational methods
Structure-guided cancer immunotherapy design with HLA-Arena and CrossDome
This study is looking for better ways to help your immune system fight Acute Myeloid Leukemia (AML) by finding safe and effective targets that can boost T-cells, using new technology to make the process easier and more effective.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10866859 on NIH RePORTER |
What this research studies
This research focuses on improving T-cell-based therapies for cancer, specifically targeting Acute Myeloid Leukemia (AML). It aims to identify safe and effective peptide targets that can activate T-cells without causing harmful side effects. By utilizing advanced structural modeling and machine learning techniques, the study will create a new computational environment called HLA-arena 2.0, which integrates various bioinformatics methods to enhance the discovery of tumor-associated antigens. This innovative approach seeks to overcome current limitations in identifying effective immunotherapy targets.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Acute Myeloid Leukemia who are seeking innovative treatment options.
Not a fit: Patients with other types of cancer or those who do not have a diagnosis of Acute Myeloid Leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of safer and more effective immunotherapies for patients with Acute Myeloid Leukemia.
How similar studies have performed: Other research has shown promise in using structural modeling and machine learning for immunotherapy design, indicating that this approach could be a significant advancement in the field.
Where this research is happening
Houston, United States
- University of Houston — Houston, United States (Active)
Researchers
- Principal investigator: Antunes, Dinler — University of Houston
- Study coordinator: Antunes, Dinler
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.